红花多糖抑制人乳腺癌细胞MCF-7增殖及对其转移能力的影响
|
摘要
目的：探讨乳腺癌组织中nm23-H1、c-erbB2和MMP-9蛋白表达及其与相关指标和转移的关系；研究红花多糖(SPS)、表阿霉素(EPI)对人乳腺癌细胞MCF-7增殖、凋亡的影响,观察凋亡和转移相关基因BAX、Bcl-2、MMP-9、 nm23-H1mRNA和蛋白表达变化,通过Transwell小室法证实红花多糖、表阿霉素对乳腺癌细胞转移能力的影响,并进行对比及统计学分析,明确中药红花多糖与化疗药物表阿霉素对乳腺癌细胞作用的区别,探讨红花多糖抗MCF-7细胞作用及规律。
方法：
1.随机抽取乳腺癌组织标本120例,正常乳腺组织标本77例。采用免疫组化SP法检测乳腺癌组织及正常乳腺组织中nm23-H1、C-erbB2和MMP-9的表达情况,结合临床病理资料,分析三者表达与年龄、临床分期、淋巴结转移等临床病理特征的关系。
2. MTT比色法观察不同浓度的红花多糖、表阿霉素对人乳腺癌MCF-7细胞体外增殖的抑制作用,并通过流式细胞仪(FCM)分析细胞凋亡。
3. Real-time PCR检测不同浓度红花多糖、表阿霉素作用于乳腺癌MCF-7细胞后BAX、Bcl-2、MMP-9、nm23-H1mRNA表达水平；western blot检测不同浓度红花多糖、表阿霉素作用于乳腺癌MCF-7细胞后BAX、Bcl-2、MMP-9、 nm23-H1蛋白表达水平。
4. Transwell小室法研究不同浓度红花多糖、表阿霉素对乳腺癌细胞MCF-7转移能力的影响。
结果：
1. nm23-H1、c-erbB2和MMP-9在乳腺癌组织中均显著表达；三者中仅C-erbB2蛋白表达与患者年龄有关；nm23-H1蛋白在早期、无淋巴结转移及远处转移的乳腺癌中呈高表达,而c-erbB2和MMP-9则在晚期、有淋巴结转移及远处转移的乳腺癌中呈现高表达。
2.红花多糖、表阿霉素均能抑制乳腺癌MCF-7细胞增殖。表阿霉素对MCF-7细胞的抑制作用随浓度的升高抑制作用增强,随着时间进行作用减弱；红花多糖对MCF-7细胞的抑制作用随着时间的进行作用增强,并在一定浓度内,随着浓度的升高作用增强,超过一定浓度后作用反而降低。
3.流式细胞仪检测,MCF-7细胞经SPS、EPI作用后24h后,其早期凋亡率、细胞坏死或晚期凋亡率显著增加,呈现明显的浓度依赖性。
4.Real-time PCR和western blot检测发现,SPS、EPI作用后的MCF-7细胞的Bcl-2、MMP-9mRNA及蛋白表达量明显下降,BAX、nm23-H1mRNA表达量明显升高。
5.SPS、EPI对乳腺癌MCF-7细胞的转移能力均有一定的抑制作用。
结论：
1.c-erbB2、MMP-9高表达及nm23-H1低表达与乳腺癌发生浸润转移密切相关。联合检测这些指标可作为乳腺癌患者转移复发,早期诊断及预后判断的参考指标,同时也为抗肿瘤药物的研究提供重要靶点及理论依据。
2.中药SPS对人乳腺癌MCF-7细胞体外的抑制作用与表阿霉素有区别,SPS对MCF-7细胞的抑制随着浓度的升高、时间的延长作用增强。
3.SPS、EPI诱导人乳腺癌MCF-7细胞凋亡和坏死,作用具有剂量依赖性；同一浓度的SPS诱导乳腺癌细胞凋亡和坏死的作用较EPI弱。
4. SPS、EPI均可以诱导Bcl-2、MMP-9基因表达下降,BAX、nm23-Hl上升。
5.SPS、EPI均可以抑制乳腺癌MCF-7细胞的转移能力,二者的抑制作用无统计学差异。
Objective:
To investigate nm23-H1, c-erbB-2and MMP-9protein expression in breast cancer tissue and its relationship with the relevant indicators and transfer; to study the influence of safflower polysaccharides (SPS), epirubicin (EPI) on the proliferation and apoptosis of the human breast cancer cells MCF-7, and observe the changes of the apoptosis and metastasis related genes of BAX, Bcl-2and MMP-9, nm23-H1mRNA and protein expression, to confirm using Transwell chamber assay that safflower polysaccharide, epirubicin can suppression the metastatic ability of breast cancer cells. And make sure that Chinese medicine safflower polysaccharide has the ability of anti-MCF-7cells by certain mechanism.
Methods:
1. Random collecting120cases of breast cancer tissue samples and77cases of normal breast tissue samples. We try to use SP immunohistochemistry method to detect the expression of nm23-H1, c-erbB-2and MMP-9in breast cancer tissue and normal breast tissue. To combine with clinical and pathological data, and analysis of the three exppression with age, clinical stage, lymph node metastasis the relationship of the clinical and pathological features.
2. To observe the proliferation inhibition and apoptosis of human breast cancer MCF-7cell effected by safflower polysaccharide or epirubicin by using MTT assay and flow cytometry (FCM) analysis.
3.To detect the expression levels of BAX and Bcl-2and MMP-9, nm23-Hl mRNA in MCF-7cell by using real-time PCR; to detect the expression levels of BAX and Bcl-2and MMP-9, nm23-H1mRNA in MCF-7cell by using western blot.
4. Transwell chamber experiment was used to investigate effects on the metastatic ability of breast cancer cell line MCF-7by giving different concentrations of safflower polysaccharide or epirubicin.
Results:
1. Nm23-H1, c-erbB-2and MMP-9were highly expressed in breast cancer; only the c-erbB-2level related with age; expression of nm23-H1protein was high in the early stage of breast cancer and breast cancer with no lymph node metastasis or distant metastasis; however, expression of c-erbB-2and MMP-9were high in the late stage, lymph node metastasis and distant metastasis of breast cancer.
2. Safflower polysaccharide and epirubicin can both inhibit the proliferation of breast cancer MCF-7cell. The depressant effect of Epirubicin on MCF-7cells increased with the concentration of Epirubicin, and decreased with time; the inhibition of safflower polysaccharide on MCF-7cells increased with time progresses, and in a certain concentration, as the concentration increased, the enhanced role increased, till the concentration achieved or larger than the certain concentration, and then the inhibition effect decreased.
3. Be treated wiht SPS or EPI for24hours, flow cytometry was applied. Results showed that the early apoptosis rate, cell necrosis and late apoptosis rate of MCF-7cells were significantly increased, showing a significant concentration-dependent.
4. Real-time PCR and western blot results showed that, treated with SPS and EPI, the expression of Bcl-2and MMP-9(both in RNA and protein) were decreased, and the level of BAX and nm23-H1mRNA were increased.
5. Both SPS and EPI had the ability to inhibit metabasis of breast cancer MCF-7cells.
Conclusion:
1. High expression of c-erbB-2and MMP-9and low expression of nm23-H1were closely related to invasion and metastasis in breast cancer. Testing these index can be helpful in early diagnosis of metastasis and recurrence of breast cancer, providing evidence for estimating the outcome, and providing theoretical basis on anticancer targets of reference
2. Inhibition effect of Traditional Chinese medicine SPS and EPI on breast cancer cell MCF-7cells was significant different. The inhibition of safflower polysaccharide on MCF-7cells increased with time progresses only in a certain concentration.
3. Both SPS and EPI induced human breast MCF-7apoptosis and necrosis in a dose dependent; the effect of apoptosis and necrosis by SPS is weaker than that by EPI.
4. Both SPS and EPI can induce Bcl-2and MMP-9gene lowly express, and induce BAX and nm23-H1gene highly express.
5. SPS and EPI both can inhibit the metastatic potentia of breast cancer MCF-7cells, with no significant difference.
方法：
1.随机抽取乳腺癌组织标本120例,正常乳腺组织标本77例。采用免疫组化SP法检测乳腺癌组织及正常乳腺组织中nm23-H1、C-erbB2和MMP-9的表达情况,结合临床病理资料,分析三者表达与年龄、临床分期、淋巴结转移等临床病理特征的关系。
2. MTT比色法观察不同浓度的红花多糖、表阿霉素对人乳腺癌MCF-7细胞体外增殖的抑制作用,并通过流式细胞仪(FCM)分析细胞凋亡。
3. Real-time PCR检测不同浓度红花多糖、表阿霉素作用于乳腺癌MCF-7细胞后BAX、Bcl-2、MMP-9、nm23-H1mRNA表达水平；western blot检测不同浓度红花多糖、表阿霉素作用于乳腺癌MCF-7细胞后BAX、Bcl-2、MMP-9、 nm23-H1蛋白表达水平。
4. Transwell小室法研究不同浓度红花多糖、表阿霉素对乳腺癌细胞MCF-7转移能力的影响。
结果：
1. nm23-H1、c-erbB2和MMP-9在乳腺癌组织中均显著表达；三者中仅C-erbB2蛋白表达与患者年龄有关；nm23-H1蛋白在早期、无淋巴结转移及远处转移的乳腺癌中呈高表达,而c-erbB2和MMP-9则在晚期、有淋巴结转移及远处转移的乳腺癌中呈现高表达。
2.红花多糖、表阿霉素均能抑制乳腺癌MCF-7细胞增殖。表阿霉素对MCF-7细胞的抑制作用随浓度的升高抑制作用增强,随着时间进行作用减弱；红花多糖对MCF-7细胞的抑制作用随着时间的进行作用增强,并在一定浓度内,随着浓度的升高作用增强,超过一定浓度后作用反而降低。
3.流式细胞仪检测,MCF-7细胞经SPS、EPI作用后24h后,其早期凋亡率、细胞坏死或晚期凋亡率显著增加,呈现明显的浓度依赖性。
4.Real-time PCR和western blot检测发现,SPS、EPI作用后的MCF-7细胞的Bcl-2、MMP-9mRNA及蛋白表达量明显下降,BAX、nm23-H1mRNA表达量明显升高。
5.SPS、EPI对乳腺癌MCF-7细胞的转移能力均有一定的抑制作用。
结论：
1.c-erbB2、MMP-9高表达及nm23-H1低表达与乳腺癌发生浸润转移密切相关。联合检测这些指标可作为乳腺癌患者转移复发,早期诊断及预后判断的参考指标,同时也为抗肿瘤药物的研究提供重要靶点及理论依据。
2.中药SPS对人乳腺癌MCF-7细胞体外的抑制作用与表阿霉素有区别,SPS对MCF-7细胞的抑制随着浓度的升高、时间的延长作用增强。
3.SPS、EPI诱导人乳腺癌MCF-7细胞凋亡和坏死,作用具有剂量依赖性；同一浓度的SPS诱导乳腺癌细胞凋亡和坏死的作用较EPI弱。
4. SPS、EPI均可以诱导Bcl-2、MMP-9基因表达下降,BAX、nm23-Hl上升。
5.SPS、EPI均可以抑制乳腺癌MCF-7细胞的转移能力,二者的抑制作用无统计学差异。
Objective:
To investigate nm23-H1, c-erbB-2and MMP-9protein expression in breast cancer tissue and its relationship with the relevant indicators and transfer; to study the influence of safflower polysaccharides (SPS), epirubicin (EPI) on the proliferation and apoptosis of the human breast cancer cells MCF-7, and observe the changes of the apoptosis and metastasis related genes of BAX, Bcl-2and MMP-9, nm23-H1mRNA and protein expression, to confirm using Transwell chamber assay that safflower polysaccharide, epirubicin can suppression the metastatic ability of breast cancer cells. And make sure that Chinese medicine safflower polysaccharide has the ability of anti-MCF-7cells by certain mechanism.
Methods:
1. Random collecting120cases of breast cancer tissue samples and77cases of normal breast tissue samples. We try to use SP immunohistochemistry method to detect the expression of nm23-H1, c-erbB-2and MMP-9in breast cancer tissue and normal breast tissue. To combine with clinical and pathological data, and analysis of the three exppression with age, clinical stage, lymph node metastasis the relationship of the clinical and pathological features.
2. To observe the proliferation inhibition and apoptosis of human breast cancer MCF-7cell effected by safflower polysaccharide or epirubicin by using MTT assay and flow cytometry (FCM) analysis.
3.To detect the expression levels of BAX and Bcl-2and MMP-9, nm23-Hl mRNA in MCF-7cell by using real-time PCR; to detect the expression levels of BAX and Bcl-2and MMP-9, nm23-H1mRNA in MCF-7cell by using western blot.
4. Transwell chamber experiment was used to investigate effects on the metastatic ability of breast cancer cell line MCF-7by giving different concentrations of safflower polysaccharide or epirubicin.
Results:
1. Nm23-H1, c-erbB-2and MMP-9were highly expressed in breast cancer; only the c-erbB-2level related with age; expression of nm23-H1protein was high in the early stage of breast cancer and breast cancer with no lymph node metastasis or distant metastasis; however, expression of c-erbB-2and MMP-9were high in the late stage, lymph node metastasis and distant metastasis of breast cancer.
2. Safflower polysaccharide and epirubicin can both inhibit the proliferation of breast cancer MCF-7cell. The depressant effect of Epirubicin on MCF-7cells increased with the concentration of Epirubicin, and decreased with time; the inhibition of safflower polysaccharide on MCF-7cells increased with time progresses, and in a certain concentration, as the concentration increased, the enhanced role increased, till the concentration achieved or larger than the certain concentration, and then the inhibition effect decreased.
3. Be treated wiht SPS or EPI for24hours, flow cytometry was applied. Results showed that the early apoptosis rate, cell necrosis and late apoptosis rate of MCF-7cells were significantly increased, showing a significant concentration-dependent.
4. Real-time PCR and western blot results showed that, treated with SPS and EPI, the expression of Bcl-2and MMP-9(both in RNA and protein) were decreased, and the level of BAX and nm23-H1mRNA were increased.
5. Both SPS and EPI had the ability to inhibit metabasis of breast cancer MCF-7cells.
Conclusion:
1. High expression of c-erbB-2and MMP-9and low expression of nm23-H1were closely related to invasion and metastasis in breast cancer. Testing these index can be helpful in early diagnosis of metastasis and recurrence of breast cancer, providing evidence for estimating the outcome, and providing theoretical basis on anticancer targets of reference
2. Inhibition effect of Traditional Chinese medicine SPS and EPI on breast cancer cell MCF-7cells was significant different. The inhibition of safflower polysaccharide on MCF-7cells increased with time progresses only in a certain concentration.
3. Both SPS and EPI induced human breast MCF-7apoptosis and necrosis in a dose dependent; the effect of apoptosis and necrosis by SPS is weaker than that by EPI.
4. Both SPS and EPI can induce Bcl-2and MMP-9gene lowly express, and induce BAX and nm23-H1gene highly express.
5. SPS and EPI both can inhibit the metastatic potentia of breast cancer MCF-7cells, with no significant difference.
引文
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics,2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. Epub 2009 May 27
2.汤钊猷.现代肿瘤学[M].复旦大学出版社,2011：892
3. GLOBOCAN 2008:Breast Cancer Incidence, Mortality and Prevalence Worldwide in 2008 Summary[EB/OL]. http://globocan.iarc.fr/factsheet.asp
4.杨玲,李连弟,陈育德,D. M. Parkin,中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,(6).
5.刘健,谷俊朝.地理信息系统在乳腺癌流行病学中的应用进展[J].国际外科学杂志,2009,36(11):776-778.DOI:10.3760/cma.j.issn.1673-4203.2009.11.019.
6. McGurieWL. Breast cancer prognostic factors:evaluatio guidelines. Natl Cancer Inst,1991, 83(3):154-155
7.陈俊强,罗善山,刘金碌,林进令,曾健,陈军,.应用组织芯片进行乳腺癌分子分型的研究[J].中国普通外科杂志,2010,(11).
8.徐安,李楠,.乳腺癌转移相关基因的研究进展[J].中国肿瘤生物治疗杂志,2010,(2).
9.储大同.单克隆抗体——肿瘤靶向治疗的新方向[J].中华肿瘤杂志,2004,(3).
10.孙燕,李丽庆,宋三泰,许立功,于世英,王金万,江泽飞,印季良,熊慧华.注射用曲妥珠单抗治疗晚期乳腺癌临床验证结果[J].中华肿瘤杂志,2003,(6).
11.孙燕.中医中药在肿瘤综合治疗中的应用[J].中国中西医结合杂志,1997,(6).
12.杨志福,梅其炳.红花有效成分及药理作用[J].西北药学杂志,2001,16(3)：131-133.
13.石学魁,阮殿清,王亚贤,等.红花多糖抗肿瘤活性及对T739肺癌鼠CTL, NK细胞杀伤活性的影响[J].中国中药杂志,2010,35(2)：215-218.
14.周明瑶,阮殿清,陈德欣,等.红花多糖对人PBMC增殖活性及NK, LAK细胞杀伤活性的影响[J].中医药信息,2010,27(1)：47-49.
15.石学魁,阮殿清,陶冀,等.红花多糖对人PBMC增殖活性及分泌细胞因子的影响[J].天津中医药,2010,27(4)：337-339.
16.谢雪怡,宋少章,韩锐,孙燕.表阿霉素临床药理学分析[J].中国临床药理学杂志,1988,(1).
17.沈琳,金懋林,张晓东,李洁,刘庆森,胡国清,吴晴,付强,陆震宇,李杰.澳沙利铂联合表阿霉素5-FU/CF治疗晚期胃癌的临床探讨[J].中国肿瘤临床,2005,(8).
18.康欣梅,张清媛,赵文辉.紫杉醇联合表阿霉素与诺维本联合表阿霉素治疗晚期乳腺癌的临床对比观察[J].中国肿瘤临床,2004,(18).
19.庞丹梅,邓燕明,白永红.吡喃阿霉素、表阿霉素及阿霉素为主联合化疗方案治疗非霍奇金淋巴瘤[J].实用癌症杂志,2001,(2).
20.刘本春.表阿霉素在膀胱癌治疗及复发预防中的应用[J].中国癌症杂志,1998,(3).
21.杨秋莉,王学芬,张向农,.古代中医对乳腺癌的认识[J].中国中医基础医学杂志,2010,(5).
22.丁波.中医治疗恶性肿瘤的现代研究进展[J].解放军医药杂志.2011(S1).
23.卢雯平,陈长怀,花宝金,杨宗艳,石闻光.乳腺癌的中医治疗思路及方法[J].中国肿瘤,2003,(6).
24.李桃花,.浅谈乳腺癌的中医学术源流[J].吉林中医药,2009,(12).
25.张向农,范磊,廖娟等.乳腺癌古代中医文献考略[J].肿瘤研究与临床,2009,21(4)：278-282
26.陈建萍,赵淑华,卓灏柏,王志宇,郑骁,林毅,.中医防治乳腺癌复发与转移的策略与方法[J].环球中医药,2011,(2).
27.张勇.乳腺癌的中医治疗[J].光明中医,2009,24(1)：178-181.
28.卢雯平,陈长怀,花宝金等.乳腺癌的中医治疗思路及方法[J].中国肿瘤,2003,12(6)：331-333.
29.聂有智.乳腺癌的中医辨证施治[J].中国临床医生,2011,39(10)：5-7
30.王亚非,姚祖培,黄新中等.旋复代赭汤加味防治恶性肿瘤化疗呕吐反应的临床研究[J].中国中西医结合杂志,1998,18(5)：273
31.张小玲.癌症化疗病人的扶正四法.江苏中医,1991,12(12)：20.
32.李雅琴,彭世萍.参芪扶止注射液配合乳腺癌术后化疗35例[J].中国中西医结合杂志,2002,22(11)：827.
33.朱琨,李康,党诚学等.参芪扶止注射液对乳腺癌术后行CEF方案化疗患者免疫功能的影响[J].现代肿瘤医学,2008,16(10)：1712-1714
34.凌昌全,陈连起,陈哲,等.四生汤抗放疗毒副反应的临床和实验研究.中医杂志,1993,(1)：34.
35.董丽华,吴镇凤,刘锋,等.养阴生血饮与放疗合并应用治疗恶性肿瘤的临床观察.白求恩医科大学学报,1998,24(2)：183-184.
36.唐汉钧.乳腺癌的中医临床与实验研究[J].中医药学刊,2003,21(2)：168-172.
37.宝鲁日,师永红,.乳腺癌转移相关基因的研究进展[J].内蒙古医学院学报,2011,(4).
38.祁明浩,徐力.乳腺癌防转移的中医现代研究进展[J].现代中医药,2010,30(1)：66-68.
39.王秀峰,周钱梅,苏式兵等.黄芩素抑制人乳腺癌细胞侵袭和迁移的实验研究[J].中国药理 学通报,2010,26(6)：745-750.
40.郭保凤,刘胜,叶依依等.中药提取物配伍对乳腺癌MDA-MB-231BO细胞侵袋作用的影响及其机制[J].中西医结合学报,2011,09(10)：1110-1117
41.姚暄,贾立群,谭煌英,高福云,崔建,李环.淫羊覆对乳腺癌骨转移大鼠肿瘤生长和骨破坏的影响[J].北京中医药,2008,(11).
42. Abrahamsen JF, Bakken AM, Bruserud Φ,et al.Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases[J].Bone Marrow Transplant,2002,29(2):165-171.
43. Zwick E, Bange J, Ullrich A, et al.Receptor tyrosine kinase as targets for anticancer drugs[J].Trends Mol Med,2002,8(1):17-23
44.陈俊霞,夏俊,刘基巍等.人参皂甙Rg3诱导乳腺癌细胞系MCF-7凋亡的实验研究[J].癌变·畸变·突变,2005,17(4)：213-216.
45.纪慧,田华,王玉春等.墨西哥仙人掌多糖对人乳腺癌MCF-7细胞凋亡坏死诱导作用的研究[J].中国现代医生,2011,49(23)：14-15.
46.宋玉仙,窦环,刘贤饮等.灵芝孢子油对MCF-7细胞凋亡及迁移的影响[J].中医药信息,2011,28(2)：91-94.
47.吴其年,黄炜,黄敏珊等.熊果酸对人乳腺癌细胞增殖、凋亡和细胞内游离Ca2+的影响[J].肿瘤学杂志,2004,10(3)：145-147.
48. Folkman J. Tumor angiogenesis:therapeutic implications. N Engl J Med.1971 Nov 18;285(21):1182-6. Review. PubMed PMID:4938153.
49.张清媛,孙理,王志华等.人参皂甙Rg3与环磷酰胺并用对EMT-6乳腺癌小鼠肿瘤血管生成的影响[J].中国临床康复,2004,8(29)：6395-6397.
50.林晓燕,宋和平,胡赞宏等.去甲斑蝥素对人乳腺癌血管生成的抑制作用[J].中国癌症杂志,2007,17(11)：847-850.
51.吴凯南,林辉,吴恺南等.槲皮素对实验性乳腺癌中血管生成抑制作用的研究[J].中国肿瘤临床,2001,28(4)：295-299.
52.林芳,钱之玉,丁健等.二氢青蒿素对人乳腺癌MCF-7细胞的体外抑制作用[J].中国新药杂志,2002,11(12)：934-936.
53.韦达,俞军,俞乔等.姜黄素对人乳腺癌MCF-7细胞增殖抑制作用及机制研究[J].山东中医药大学学报,2008,32(2)：154-156.
54.李江滨,何冬梅,赖银璇等.翡翠贻贝多糖抑制乳腺癌MCF-7细胞增殖的实验研究[J].中国 现代药物应用,2011,05(1)：17-18.
55.王升启.基因芯片技术及应用研究进展[J].生物工程进展,1999,(4).
56.冯青青,张力图,.基因芯片技术在乳腺癌研究中的应用[J].中国癌症防治杂志,2011,(2).
57.叶丽虹,尤嘉琮,乔玲等.应用基因表达谱芯片从不同转移能力的乳腺癌细胞中筛选转移相关基因[J].生物化学与生物物理进展,2005,32(5)：421-42
58.陈剑英,张波,王国斌等.人类乳腺癌基因表达分析[J].中华实验外科杂志,2005,22(4)：429-431.
59.闫实,韩金祥,高雪芹等.用肿瘤转移基因芯片筛查乳腺癌转移相关基因表达谱[J].山东大学学报(医学版),2004,42(3)：269-273
60.朱园园.Bcl-2家族在肿瘤进展和治疗中的意义[J].国际肿瘤学杂志,2008,35(10)：726-728.
61. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science.1985 Jun 21;228(4706):1440-3
62. Rajah TT, Peine KJ, DU N, Serret CA, Drews NR. Physiological Concentrations of Genistein and 17β-Estradiol Inhibit MDA-MB-231 Breast Cancer Cell Growth by Increasing BAX/BCL-2 and Reducing pERK1/2. Anticancer Res.2012 Apr;32(4):1181-91.
63. Wang XC, Li Y, Fan LQ, Tan BB, Li Z, Liu Y, Zhang ZD. Integrase interactor 1 regulates proliferation, apoptosis and invasion in gastric cancer cells. Chin Med J (Engl).2012 Feb;125(3):527-32.
64. Moreno A, Figueras A, Lloveras B, Escobedo A, Griera E, Sierra A, Fabra A. Apoptosis in ductal carcinoma in situ of the breast. Breast J.2001 Jul-Aug;7(4):245-8.
65. Chami M, Prandini A, Campanella M, Pinton P, Szabadkai G, Reed JC, Rizzuto R. Bcl-2 and Bax exert opposing effects on Ca2+ signaling, which do not depend on their putative pore-forming region. J Biol Chem.2004 Dec 24;279(52):54581-9.
66.张玲,李理,张秀英,.Bcl-2在乳腺癌中的表达及其与肿瘤多药耐药关系的研究[J].实用肿瘤杂志,2009,(3).
67.[2]胡军,金伟,杨佩满.β-榄香烯逆转人乳腺癌MCF-7/ADM细胞对阿霉素耐药性的研究[J].中华肿瘤杂志,2004,(5).
68.[3]蔡宇,杨燕霞,梁少玲,徐炎.补骨脂素对乳腺癌多药耐药细胞株Bcl-2基因蛋白表达的影响[J].中药材,2004,(11).
69. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003 Jan-Feb;9(1):33-41.
70. Bodur C, Basaga H. Bcl-2 inhibitors:emerging drugs in cancer therapy. Curr Med Chem. 2012 Apr 1; 19(12):1804-20.
71. Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther.2003 Jul-Aug;2(4 Suppl 1):S105-14.
72. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, Straten PT. Immunogenicity of Bcl-2 in patients with cancer. Blood.2005 Jan 15;105(2):728-34. Epub 2004 Sep 14.
73. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene.2003 Nov 20;22(52):8441-7. PubMed PMID:14627985.
74. Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol.2003 Apr;22(4):875-81.
75.张立涛,高东宸.乳腺癌中c-myc和bcl-2表达及其意义[J].临床和实验医学杂志,2005,(1).
76. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol.1994 Nov; 145(5):1191-8. PubMed PMID:7977649;
77.沈镇宙,邵志敏主编.现代乳腺肿瘤学进展[M].第1版.上海：上海科技文献出版社,2002：353-355
78. Gee JM, Ellis IO, Robertson JF, Willsher P, McClelland RA, Hewitt KN, Blarney RW, Nicholson RI. Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer.1995 Aug 22;64(4):269-73
79. Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene—amplified breast cancer cells. Clin Cancer Res.2004 Nov 15;10(22):7747-56.
80. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg.2004 Jan;198(1):83-90.
81. Grimm D, Wehland M, Pietsch J, Infanger M, Bauer J. Drugs interfering with apoptosis in breast cancer. Curr Pharm Des.2011;17(3):272-83.
82. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with aconserved homolog, Bax, that accelerates programmed cell death. Cell.1993 Aug 27;74(4):609-19.
83. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res.2002 Jan 15;62(2):466-71.
84. Sarkar FH, Rahman KM, Li Y. Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells. J Nutr.2003 Jul; 133(7 Suppl):2434S-2439S.
85. Yu W, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Res.2003 May 15;63(10):2483-91.
86.刘雪梅,黄剑飞Bcl-2,Bax在乳腺癌中表达的临床意义[J].河南肿瘤学杂志,2005,18(1)：14-16.
87. Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S. Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res.1997 Jul-Aug;17(4A):2499-505.
88. Iwata H, Kobayashi S, Iwase H, Okada Y. [The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis]. Nihon Rinsho.1995 Jul;53(7):1805-10
89. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers:outside-in signaling and relationship to tumor progression. Biochim Biophys Acta.2012 Jan;1825(1):29-36. Epub 2011 Oct 12
90. Kim S, Han J, Lee SK, Choi MY, Kim J, Lee J, Jung SP, Kim JS, Kim JH, Choe JH, Lee JE, Nam SJ. Berberine Suppresses the TPA-Induced MMP-1 and MMP-9 Expressions Through the Inhibition of PKC-a in Breast Cancer Cells. J Surg Res.2011 Dec 30.
91. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature.1980 Mar 6;284(5751):67-8.
92. Sreenath T, Matrisian LM, Stetler-Stevenson W, Gattoni-Celli S, Pozzatti RO. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res.1992 Sep 15;52(18):4942-7.
93. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res.2005 Nov-Dec;25(6B):4101-5
94.王岩,刘晓霞,侯止文,柳春晖,马秀萍,陈丽萍,贾支红,方虹.基质金属蛋白酶及其抑制剂在乳腺癌转移、浸润中的作用[J].临床与实验病理学杂志,2002,(3).
95.周波,谢菲,郭嘉嘉,杨德启,Kiss-1及nm23表达与乳腺癌淋巴结转移的关系[J].中国癌症杂志,2009,(3).
96.周晓雷,张晓东,叶丽虹,.DKK-1通过上调nm23表达抑制乳腺癌细胞迁移[J].中国生物化学与分子生物学报,2010,(2).
97.崔殿龙,赵家宏.乳腺癌中nm23-H1基因的表达研究[J].肿瘤防治研究,2002,29(1)：25-26.
98.彭永红,袁宏银,杨国樑CD44V6、nm23-H_1及ER在乳腺癌的表达及其与预后的关系[J].实用肿瘤杂志,2002,(3).
99.王艺蓉,白咸勇.红花的作用及机制研究进展[J].滨州医学院学报,2009,32(6)：451-453.
100.姜建双,夏鹏飞,冯子明,等.红花化学成分研究[J].中国中药杂志,2008,33(24)：2911-2913.
101.奚胜艳,张前,王淳,等.红花抗肿瘤之应用与作用机理探析[J].中华中医药学刊,2008,26(9)：1916-1917
102.王文杰.红花水煎剂对肿瘤组织病理学改变及血管生成的影响[J].山西中医,2007,23(6)：59-60.
103.靳祎,石少慧,王恩军,等.花注射液对人宫颈癌细胞株Hela体外增殖的影响[J].军医进修学院学报,2007,28(6)：448449.
104.奚胜艳,张前,刘朝阳,等.羟基红花黄色素A对裸鼠人胃腺癌BGC-823移植瘤抑制作用的研究[J].北京中医药大学学报,2009,32(5)：331-335,插页3.
105.黄虹,俞曼雷,翟世康,等.红花多糖的免活性作用[J].现代免疫学,1982,(6)：7-8.
106.何素芳,王志刚,任爱农,等.红花多糖对H22荷瘤小鼠的抑瘤作用及瘤细胞VEGF,Ki67表达的影响[J].中国中药杂志,2009,34(6)：795-797.
107.张红春.红花多糖抗肿瘤作用的免疫机理研究[D].黑龙江中医药大学硕士学位论文, 2005.
108.李坤,郭红艳,吴琦,等PI3Kp55γN末端氨基酸过表达对胃癌MGC803细胞迁移的影响[J].世界华人消化杂志,2009,17(33)：3381-3386.
109.杨志福,梅其炳.红花有效成分及药理作用[J].西北药学杂志,2001,16(3)：131-133.
110. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol.1999 Jul;17(7):1983-7.
111.谢菲,黄东兰,岑东芝,张积仁,.乳腺癌转移相关基因的文献计量分析[J].重庆医学,2012,(5).
112.肖建军,陶敏,段卫明,周靖,胡一河,.乳腺癌绝经前后c-erbB-2、ER、PR的表达及与预后的相关性[J].肿瘤防治研究,2009,(8).
113.杨丽芳,宋三泰,李晓兵,江泽匕,刘晓晴,马维娜,乔西平,郭斯启,.284例原发乳腺癌c-erbB2蛋白的表达及其与预后的关系[J].中华肿瘤杂志,2006,(4).
114.江泽飞,边莉,.乳腺癌表皮生K因子受体-2分子靶向治疗临床应用策略[J].中华普外科手术学杂志(电子版),2011,(4).
115.张晓莉,李玉婷,王亚贤,等.红花多糖的提取与含量测定[J].中国实验方剂学杂志,2010,16(7)：19-21.
116.段志芳,章炜中,黄丽华.紫背天葵多糖提取与含量测定[J].中成药,2007,29(2)：274.
117.彭评志,.MTT法检测乳腺癌细胞的体外药物敏感率[J].广西医学,2008,(12).
118.司徒镇强,吴军正主编.细胞培养[M].第一版,西安：世界图书出版西安公司,2004,3：250-252.
119. Twentyman PR, Bleehen NM.Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin[corrected][J].Eur J Cancer,1991,27(12):1639-1642.
120. http://chiryo.phar.nagoya-cu.ac.jp/javastat/Graded50-j.htm
121. Zhang KZ,Xu JH,Huang XW,et al.Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells[J].Acta Pharmacol Sin,2007,28(1):105-110.
122. Chen GG,Sin FL,Leung BC,et al.Glioblastoma cells deficient in DNA-dependent protein kinase are resistant to cell death[J].J Cell Phystol,2005,203(1):127-132.
123.石学魁.红花多糖诱导人胃癌SGC-7901细胞凋亡及对AKT信号的影响[D].黑龙江中 医药大学：黑龙江中医药大学,2011.
124.田海梅,傅军,王燕,石晓燕,曹冬燕,徐兵河,张保宁,张伟.三种药物对人乳腺癌细胞体外杀伤作用比较[J].中国肿瘤临床,2004,(19).
125.Baxa DM, Luo X, Yoshimura FK.Genistein induces apoptosis in T lymphoma cells via mitochondrial damage[J].Nutr Cancer,2005,51(1):93-101.
126.李连弟,饶克勤.中国11市县肿瘤发病和死亡登记资料统计分析(1988年-1992年)[J].中国肿瘤,2000,(10).
127.吕国宝.红花注射液的临床新用途[J].山东医药,2005,(22).
128.红花(Safflower)[J]国外医药(植物药分册),2004,(2).
129. Kang JK.Park YH.Choi SW,et al.Resveratrol derivatives potently induce apoptosis in human promyelocytic leukemia cells[J].Exp Mol Med.2003,35(6):467-474.
130. Xia DY, Sanders A, Shah, M, et al.Rela-time polymerase chain reaction analysis reveals an evolution of cytokine mRNA production in allograft acceptor mice[J].Transplantation,2001, 72 (5):907-914.
131.刘吉成.低分子量姬松茸多糖抗肿瘤转移作用及其分子机制研究[D].北京中医药大学博士学位论文,2006：77-78
132.张翠梅.苦参碱诱导K562细胞γ珠蛋白基因表达和向红系分化的研究[D].广州：南方医科大学博士学位论文,2007：38.
133.吴峰,王清明,范国才,陈吉中,陈惠鹏,.紫杉醇诱导MCF-7乳腺癌细胞凋亡的蛋白质组研究[J].中华肿瘤杂志,2006,(6).
134.Hou Q, Cymbalyuk E, Hsu SC, et al.Apoptosis modulatory activities of transiently expressed Bcl-2:roles in cytochrome C release and Bax regulation [J].Apoptosis, 2003,8 (6):617-629.
135.[102]赵晓艳,胡玉娜,康向东,等.熊果酸诱导人胃癌BGC823细胞凋亡及其作用机制初探[J].中国癌症杂志,2010,20(2)：101-104.
136. Rawat S, Gray C, Johnson TS, et al.Apoptosis and expression of BCL-2 and BAX in cyclosporine-induced experimental renal fibrosis[J].Transplant Proc,2003,35(1):187-188.
137.朱艳琴,刘粉霞,徐玉芳,等.苦参素诱导人胃癌MGC-803细胞凋亡的体内外实验研究[J].中国药学杂志,2011,46(1)：28-30.
138.于观贞,王杰军,陈颖,倪灿荣,朱明华,.转移相关基因nm23和P53及S100A4在晚期胃癌中的表达及与侵袭转移的相关性研究[J].中华胃肠外科杂志,2006,(2).
139.陈晓峰,丁嘉安,王海峰,何国钧,周清华,张尚福.肺癌术后转移及预后与转移抑制基因nm23和nm23-H_1的关系[J].中华实验外科杂志,2002,(1).
140.易基群,曾波航,杨晓明,方嫩.nm23-H-1和nm23-H-2在人乳腺癌中的表达及其临床意义[J].中国癌症杂志,2001,(1).
141.杨进益,章咏裳,李韶,周荣祥,周四维,侯成玉,.膀胱移行细胞癌nm23-H1和nm23-H2基因表达的检测及临床意义[J].中华实验外科杂志,1998,(3).
142.聂强,朱文,刘伦旭,付军科,李定彪,李印,陈军,刘红雨,周清华,.nm23-H1基因转染对人高转移大细胞肺癌细胞株生物学行为的影响及作用机理[J].中国肺癌杂志,2008,(3).
143.亚威,徐广‘涛,吕仕才,潘晓燕,nm23、BRCA-1和ki-67在乳腺癌中的表达及临床意义[J].实用肿瘤杂志,2011,(1).
144.周士珍,吴强,吴正升,凌晓光,杨枫.乳腺癌中环氧化酶-2的表达及其与VEGF、MVD、 MMP-9、TIMP-1的关系[J].临床与实验病理学杂志,2005,(4).
145.王祥军,吴新勇,何长青,蔡安庆,.CD147和MMP-9在乳腺癌中的表达及其与微血.管生成的相关性研究[J].现代肿瘤医学,2010,(7).
146.梁运霞,陈茂怀,黄博,吴贤英,.细胞外基质金属蛋白酶诱导因子及金属蛋白酶-9在乳腺癌中的表达及其意义[J].癌变.畸变.突变,2007,(4).
147.王岩,刘晓霞,侯正文,柳春晖,马秀萍,陈丽萍,贾支红,方虹.基质金属蛋白酶及其抑制剂在乳腺癌转移、浸润中的作用[J].临床与实验病理学杂志,2002,(3).
148.葛凤霞,王海,冯悦年,栾风云,金岩,冯晓梅MMP-2、MMP-9和Ⅳ型胶原在乳腺癌中的表达及其意义[J].临床肿瘤学杂志,2003,(3).
149.徐峰,黄波,王劲等.红花注射液治疗冠心病心绞痛疗效观察[J].人民军医,2004,47(6)：318-319
150.齐菲菲,贺福初,姜颖,.肿瘤转移研究的现状与趋势[J].生物化学与生物物理进展,2009,(10).
151.温玉明,潘剑,华成舸,陈绍维,王吕美VEGF-C在舌鳞癌中的表达及其意义[J].中国口腔颌面外科杂志,2003,(1).
152.汤钊猷.复发与转移——原发性肝癌研究的一个重点[J].中华肝胆外科杂志,1999,(1).
153.朱延波,王瑞年.肿瘤浸润、转移与细胞外基质关系[J].上海第二医科大学学报,1992,(2).
154.唐旭东,周克元,侯敢,等.白藜芦醇诱导鼻咽癌细胞CNE-2Z凋亡的线粒体机制[J].中国药理学与毒理学杂志,2004,18(3)：171-177.
155.朱峰.基质金属蛋白酶及其组织抑制物与肿瘤侵袭转移[J].国外医学.临床生物化学与 检验学分册,2001,(5).
156.左衍海,施鑫,.恶性肿瘤转移机制研究新进展[J].医学研究生学报,2008,(3).
157.李娜,高俊岩,刘敏,.细胞凋亡和肿瘤的关系研究进展[J].当代医学,2009,(16).
2.汤钊猷.现代肿瘤学[M].复旦大学出版社,2011：892
3. GLOBOCAN 2008:Breast Cancer Incidence, Mortality and Prevalence Worldwide in 2008 Summary[EB/OL]. http://globocan.iarc.fr/factsheet.asp
4.杨玲,李连弟,陈育德,D. M. Parkin,中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,(6).
5.刘健,谷俊朝.地理信息系统在乳腺癌流行病学中的应用进展[J].国际外科学杂志,2009,36(11):776-778.DOI:10.3760/cma.j.issn.1673-4203.2009.11.019.
6. McGurieWL. Breast cancer prognostic factors:evaluatio guidelines. Natl Cancer Inst,1991, 83(3):154-155
7.陈俊强,罗善山,刘金碌,林进令,曾健,陈军,.应用组织芯片进行乳腺癌分子分型的研究[J].中国普通外科杂志,2010,(11).
8.徐安,李楠,.乳腺癌转移相关基因的研究进展[J].中国肿瘤生物治疗杂志,2010,(2).
9.储大同.单克隆抗体——肿瘤靶向治疗的新方向[J].中华肿瘤杂志,2004,(3).
10.孙燕,李丽庆,宋三泰,许立功,于世英,王金万,江泽飞,印季良,熊慧华.注射用曲妥珠单抗治疗晚期乳腺癌临床验证结果[J].中华肿瘤杂志,2003,(6).
11.孙燕.中医中药在肿瘤综合治疗中的应用[J].中国中西医结合杂志,1997,(6).
12.杨志福,梅其炳.红花有效成分及药理作用[J].西北药学杂志,2001,16(3)：131-133.
13.石学魁,阮殿清,王亚贤,等.红花多糖抗肿瘤活性及对T739肺癌鼠CTL, NK细胞杀伤活性的影响[J].中国中药杂志,2010,35(2)：215-218.
14.周明瑶,阮殿清,陈德欣,等.红花多糖对人PBMC增殖活性及NK, LAK细胞杀伤活性的影响[J].中医药信息,2010,27(1)：47-49.
15.石学魁,阮殿清,陶冀,等.红花多糖对人PBMC增殖活性及分泌细胞因子的影响[J].天津中医药,2010,27(4)：337-339.
16.谢雪怡,宋少章,韩锐,孙燕.表阿霉素临床药理学分析[J].中国临床药理学杂志,1988,(1).
17.沈琳,金懋林,张晓东,李洁,刘庆森,胡国清,吴晴,付强,陆震宇,李杰.澳沙利铂联合表阿霉素5-FU/CF治疗晚期胃癌的临床探讨[J].中国肿瘤临床,2005,(8).
18.康欣梅,张清媛,赵文辉.紫杉醇联合表阿霉素与诺维本联合表阿霉素治疗晚期乳腺癌的临床对比观察[J].中国肿瘤临床,2004,(18).
19.庞丹梅,邓燕明,白永红.吡喃阿霉素、表阿霉素及阿霉素为主联合化疗方案治疗非霍奇金淋巴瘤[J].实用癌症杂志,2001,(2).
20.刘本春.表阿霉素在膀胱癌治疗及复发预防中的应用[J].中国癌症杂志,1998,(3).
21.杨秋莉,王学芬,张向农,.古代中医对乳腺癌的认识[J].中国中医基础医学杂志,2010,(5).
22.丁波.中医治疗恶性肿瘤的现代研究进展[J].解放军医药杂志.2011(S1).
23.卢雯平,陈长怀,花宝金,杨宗艳,石闻光.乳腺癌的中医治疗思路及方法[J].中国肿瘤,2003,(6).
24.李桃花,.浅谈乳腺癌的中医学术源流[J].吉林中医药,2009,(12).
25.张向农,范磊,廖娟等.乳腺癌古代中医文献考略[J].肿瘤研究与临床,2009,21(4)：278-282
26.陈建萍,赵淑华,卓灏柏,王志宇,郑骁,林毅,.中医防治乳腺癌复发与转移的策略与方法[J].环球中医药,2011,(2).
27.张勇.乳腺癌的中医治疗[J].光明中医,2009,24(1)：178-181.
28.卢雯平,陈长怀,花宝金等.乳腺癌的中医治疗思路及方法[J].中国肿瘤,2003,12(6)：331-333.
29.聂有智.乳腺癌的中医辨证施治[J].中国临床医生,2011,39(10)：5-7
30.王亚非,姚祖培,黄新中等.旋复代赭汤加味防治恶性肿瘤化疗呕吐反应的临床研究[J].中国中西医结合杂志,1998,18(5)：273
31.张小玲.癌症化疗病人的扶正四法.江苏中医,1991,12(12)：20.
32.李雅琴,彭世萍.参芪扶止注射液配合乳腺癌术后化疗35例[J].中国中西医结合杂志,2002,22(11)：827.
33.朱琨,李康,党诚学等.参芪扶止注射液对乳腺癌术后行CEF方案化疗患者免疫功能的影响[J].现代肿瘤医学,2008,16(10)：1712-1714
34.凌昌全,陈连起,陈哲,等.四生汤抗放疗毒副反应的临床和实验研究.中医杂志,1993,(1)：34.
35.董丽华,吴镇凤,刘锋,等.养阴生血饮与放疗合并应用治疗恶性肿瘤的临床观察.白求恩医科大学学报,1998,24(2)：183-184.
36.唐汉钧.乳腺癌的中医临床与实验研究[J].中医药学刊,2003,21(2)：168-172.
37.宝鲁日,师永红,.乳腺癌转移相关基因的研究进展[J].内蒙古医学院学报,2011,(4).
38.祁明浩,徐力.乳腺癌防转移的中医现代研究进展[J].现代中医药,2010,30(1)：66-68.
39.王秀峰,周钱梅,苏式兵等.黄芩素抑制人乳腺癌细胞侵袭和迁移的实验研究[J].中国药理 学通报,2010,26(6)：745-750.
40.郭保凤,刘胜,叶依依等.中药提取物配伍对乳腺癌MDA-MB-231BO细胞侵袋作用的影响及其机制[J].中西医结合学报,2011,09(10)：1110-1117
41.姚暄,贾立群,谭煌英,高福云,崔建,李环.淫羊覆对乳腺癌骨转移大鼠肿瘤生长和骨破坏的影响[J].北京中医药,2008,(11).
42. Abrahamsen JF, Bakken AM, Bruserud Φ,et al.Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases[J].Bone Marrow Transplant,2002,29(2):165-171.
43. Zwick E, Bange J, Ullrich A, et al.Receptor tyrosine kinase as targets for anticancer drugs[J].Trends Mol Med,2002,8(1):17-23
44.陈俊霞,夏俊,刘基巍等.人参皂甙Rg3诱导乳腺癌细胞系MCF-7凋亡的实验研究[J].癌变·畸变·突变,2005,17(4)：213-216.
45.纪慧,田华,王玉春等.墨西哥仙人掌多糖对人乳腺癌MCF-7细胞凋亡坏死诱导作用的研究[J].中国现代医生,2011,49(23)：14-15.
46.宋玉仙,窦环,刘贤饮等.灵芝孢子油对MCF-7细胞凋亡及迁移的影响[J].中医药信息,2011,28(2)：91-94.
47.吴其年,黄炜,黄敏珊等.熊果酸对人乳腺癌细胞增殖、凋亡和细胞内游离Ca2+的影响[J].肿瘤学杂志,2004,10(3)：145-147.
48. Folkman J. Tumor angiogenesis:therapeutic implications. N Engl J Med.1971 Nov 18;285(21):1182-6. Review. PubMed PMID:4938153.
49.张清媛,孙理,王志华等.人参皂甙Rg3与环磷酰胺并用对EMT-6乳腺癌小鼠肿瘤血管生成的影响[J].中国临床康复,2004,8(29)：6395-6397.
50.林晓燕,宋和平,胡赞宏等.去甲斑蝥素对人乳腺癌血管生成的抑制作用[J].中国癌症杂志,2007,17(11)：847-850.
51.吴凯南,林辉,吴恺南等.槲皮素对实验性乳腺癌中血管生成抑制作用的研究[J].中国肿瘤临床,2001,28(4)：295-299.
52.林芳,钱之玉,丁健等.二氢青蒿素对人乳腺癌MCF-7细胞的体外抑制作用[J].中国新药杂志,2002,11(12)：934-936.
53.韦达,俞军,俞乔等.姜黄素对人乳腺癌MCF-7细胞增殖抑制作用及机制研究[J].山东中医药大学学报,2008,32(2)：154-156.
54.李江滨,何冬梅,赖银璇等.翡翠贻贝多糖抑制乳腺癌MCF-7细胞增殖的实验研究[J].中国 现代药物应用,2011,05(1)：17-18.
55.王升启.基因芯片技术及应用研究进展[J].生物工程进展,1999,(4).
56.冯青青,张力图,.基因芯片技术在乳腺癌研究中的应用[J].中国癌症防治杂志,2011,(2).
57.叶丽虹,尤嘉琮,乔玲等.应用基因表达谱芯片从不同转移能力的乳腺癌细胞中筛选转移相关基因[J].生物化学与生物物理进展,2005,32(5)：421-42
58.陈剑英,张波,王国斌等.人类乳腺癌基因表达分析[J].中华实验外科杂志,2005,22(4)：429-431.
59.闫实,韩金祥,高雪芹等.用肿瘤转移基因芯片筛查乳腺癌转移相关基因表达谱[J].山东大学学报(医学版),2004,42(3)：269-273
60.朱园园.Bcl-2家族在肿瘤进展和治疗中的意义[J].国际肿瘤学杂志,2008,35(10)：726-728.
61. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science.1985 Jun 21;228(4706):1440-3
62. Rajah TT, Peine KJ, DU N, Serret CA, Drews NR. Physiological Concentrations of Genistein and 17β-Estradiol Inhibit MDA-MB-231 Breast Cancer Cell Growth by Increasing BAX/BCL-2 and Reducing pERK1/2. Anticancer Res.2012 Apr;32(4):1181-91.
63. Wang XC, Li Y, Fan LQ, Tan BB, Li Z, Liu Y, Zhang ZD. Integrase interactor 1 regulates proliferation, apoptosis and invasion in gastric cancer cells. Chin Med J (Engl).2012 Feb;125(3):527-32.
64. Moreno A, Figueras A, Lloveras B, Escobedo A, Griera E, Sierra A, Fabra A. Apoptosis in ductal carcinoma in situ of the breast. Breast J.2001 Jul-Aug;7(4):245-8.
65. Chami M, Prandini A, Campanella M, Pinton P, Szabadkai G, Reed JC, Rizzuto R. Bcl-2 and Bax exert opposing effects on Ca2+ signaling, which do not depend on their putative pore-forming region. J Biol Chem.2004 Dec 24;279(52):54581-9.
66.张玲,李理,张秀英,.Bcl-2在乳腺癌中的表达及其与肿瘤多药耐药关系的研究[J].实用肿瘤杂志,2009,(3).
67.[2]胡军,金伟,杨佩满.β-榄香烯逆转人乳腺癌MCF-7/ADM细胞对阿霉素耐药性的研究[J].中华肿瘤杂志,2004,(5).
68.[3]蔡宇,杨燕霞,梁少玲,徐炎.补骨脂素对乳腺癌多药耐药细胞株Bcl-2基因蛋白表达的影响[J].中药材,2004,(11).
69. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003 Jan-Feb;9(1):33-41.
70. Bodur C, Basaga H. Bcl-2 inhibitors:emerging drugs in cancer therapy. Curr Med Chem. 2012 Apr 1; 19(12):1804-20.
71. Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther.2003 Jul-Aug;2(4 Suppl 1):S105-14.
72. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, Straten PT. Immunogenicity of Bcl-2 in patients with cancer. Blood.2005 Jan 15;105(2):728-34. Epub 2004 Sep 14.
73. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene.2003 Nov 20;22(52):8441-7. PubMed PMID:14627985.
74. Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol.2003 Apr;22(4):875-81.
75.张立涛,高东宸.乳腺癌中c-myc和bcl-2表达及其意义[J].临床和实验医学杂志,2005,(1).
76. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol.1994 Nov; 145(5):1191-8. PubMed PMID:7977649;
77.沈镇宙,邵志敏主编.现代乳腺肿瘤学进展[M].第1版.上海：上海科技文献出版社,2002：353-355
78. Gee JM, Ellis IO, Robertson JF, Willsher P, McClelland RA, Hewitt KN, Blarney RW, Nicholson RI. Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer.1995 Aug 22;64(4):269-73
79. Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene—amplified breast cancer cells. Clin Cancer Res.2004 Nov 15;10(22):7747-56.
80. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg.2004 Jan;198(1):83-90.
81. Grimm D, Wehland M, Pietsch J, Infanger M, Bauer J. Drugs interfering with apoptosis in breast cancer. Curr Pharm Des.2011;17(3):272-83.
82. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with aconserved homolog, Bax, that accelerates programmed cell death. Cell.1993 Aug 27;74(4):609-19.
83. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res.2002 Jan 15;62(2):466-71.
84. Sarkar FH, Rahman KM, Li Y. Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells. J Nutr.2003 Jul; 133(7 Suppl):2434S-2439S.
85. Yu W, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Res.2003 May 15;63(10):2483-91.
86.刘雪梅,黄剑飞Bcl-2,Bax在乳腺癌中表达的临床意义[J].河南肿瘤学杂志,2005,18(1)：14-16.
87. Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S. Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res.1997 Jul-Aug;17(4A):2499-505.
88. Iwata H, Kobayashi S, Iwase H, Okada Y. [The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis]. Nihon Rinsho.1995 Jul;53(7):1805-10
89. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers:outside-in signaling and relationship to tumor progression. Biochim Biophys Acta.2012 Jan;1825(1):29-36. Epub 2011 Oct 12
90. Kim S, Han J, Lee SK, Choi MY, Kim J, Lee J, Jung SP, Kim JS, Kim JH, Choe JH, Lee JE, Nam SJ. Berberine Suppresses the TPA-Induced MMP-1 and MMP-9 Expressions Through the Inhibition of PKC-a in Breast Cancer Cells. J Surg Res.2011 Dec 30.
91. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature.1980 Mar 6;284(5751):67-8.
92. Sreenath T, Matrisian LM, Stetler-Stevenson W, Gattoni-Celli S, Pozzatti RO. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res.1992 Sep 15;52(18):4942-7.
93. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res.2005 Nov-Dec;25(6B):4101-5
94.王岩,刘晓霞,侯止文,柳春晖,马秀萍,陈丽萍,贾支红,方虹.基质金属蛋白酶及其抑制剂在乳腺癌转移、浸润中的作用[J].临床与实验病理学杂志,2002,(3).
95.周波,谢菲,郭嘉嘉,杨德启,Kiss-1及nm23表达与乳腺癌淋巴结转移的关系[J].中国癌症杂志,2009,(3).
96.周晓雷,张晓东,叶丽虹,.DKK-1通过上调nm23表达抑制乳腺癌细胞迁移[J].中国生物化学与分子生物学报,2010,(2).
97.崔殿龙,赵家宏.乳腺癌中nm23-H1基因的表达研究[J].肿瘤防治研究,2002,29(1)：25-26.
98.彭永红,袁宏银,杨国樑CD44V6、nm23-H_1及ER在乳腺癌的表达及其与预后的关系[J].实用肿瘤杂志,2002,(3).
99.王艺蓉,白咸勇.红花的作用及机制研究进展[J].滨州医学院学报,2009,32(6)：451-453.
100.姜建双,夏鹏飞,冯子明,等.红花化学成分研究[J].中国中药杂志,2008,33(24)：2911-2913.
101.奚胜艳,张前,王淳,等.红花抗肿瘤之应用与作用机理探析[J].中华中医药学刊,2008,26(9)：1916-1917
102.王文杰.红花水煎剂对肿瘤组织病理学改变及血管生成的影响[J].山西中医,2007,23(6)：59-60.
103.靳祎,石少慧,王恩军,等.花注射液对人宫颈癌细胞株Hela体外增殖的影响[J].军医进修学院学报,2007,28(6)：448449.
104.奚胜艳,张前,刘朝阳,等.羟基红花黄色素A对裸鼠人胃腺癌BGC-823移植瘤抑制作用的研究[J].北京中医药大学学报,2009,32(5)：331-335,插页3.
105.黄虹,俞曼雷,翟世康,等.红花多糖的免活性作用[J].现代免疫学,1982,(6)：7-8.
106.何素芳,王志刚,任爱农,等.红花多糖对H22荷瘤小鼠的抑瘤作用及瘤细胞VEGF,Ki67表达的影响[J].中国中药杂志,2009,34(6)：795-797.
107.张红春.红花多糖抗肿瘤作用的免疫机理研究[D].黑龙江中医药大学硕士学位论文, 2005.
108.李坤,郭红艳,吴琦,等PI3Kp55γN末端氨基酸过表达对胃癌MGC803细胞迁移的影响[J].世界华人消化杂志,2009,17(33)：3381-3386.
109.杨志福,梅其炳.红花有效成分及药理作用[J].西北药学杂志,2001,16(3)：131-133.
110. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol.1999 Jul;17(7):1983-7.
111.谢菲,黄东兰,岑东芝,张积仁,.乳腺癌转移相关基因的文献计量分析[J].重庆医学,2012,(5).
112.肖建军,陶敏,段卫明,周靖,胡一河,.乳腺癌绝经前后c-erbB-2、ER、PR的表达及与预后的相关性[J].肿瘤防治研究,2009,(8).
113.杨丽芳,宋三泰,李晓兵,江泽匕,刘晓晴,马维娜,乔西平,郭斯启,.284例原发乳腺癌c-erbB2蛋白的表达及其与预后的关系[J].中华肿瘤杂志,2006,(4).
114.江泽飞,边莉,.乳腺癌表皮生K因子受体-2分子靶向治疗临床应用策略[J].中华普外科手术学杂志(电子版),2011,(4).
115.张晓莉,李玉婷,王亚贤,等.红花多糖的提取与含量测定[J].中国实验方剂学杂志,2010,16(7)：19-21.
116.段志芳,章炜中,黄丽华.紫背天葵多糖提取与含量测定[J].中成药,2007,29(2)：274.
117.彭评志,.MTT法检测乳腺癌细胞的体外药物敏感率[J].广西医学,2008,(12).
118.司徒镇强,吴军正主编.细胞培养[M].第一版,西安：世界图书出版西安公司,2004,3：250-252.
119. Twentyman PR, Bleehen NM.Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin[corrected][J].Eur J Cancer,1991,27(12):1639-1642.
120. http://chiryo.phar.nagoya-cu.ac.jp/javastat/Graded50-j.htm
121. Zhang KZ,Xu JH,Huang XW,et al.Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells[J].Acta Pharmacol Sin,2007,28(1):105-110.
122. Chen GG,Sin FL,Leung BC,et al.Glioblastoma cells deficient in DNA-dependent protein kinase are resistant to cell death[J].J Cell Phystol,2005,203(1):127-132.
123.石学魁.红花多糖诱导人胃癌SGC-7901细胞凋亡及对AKT信号的影响[D].黑龙江中 医药大学：黑龙江中医药大学,2011.
124.田海梅,傅军,王燕,石晓燕,曹冬燕,徐兵河,张保宁,张伟.三种药物对人乳腺癌细胞体外杀伤作用比较[J].中国肿瘤临床,2004,(19).
125.Baxa DM, Luo X, Yoshimura FK.Genistein induces apoptosis in T lymphoma cells via mitochondrial damage[J].Nutr Cancer,2005,51(1):93-101.
126.李连弟,饶克勤.中国11市县肿瘤发病和死亡登记资料统计分析(1988年-1992年)[J].中国肿瘤,2000,(10).
127.吕国宝.红花注射液的临床新用途[J].山东医药,2005,(22).
128.红花(Safflower)[J]国外医药(植物药分册),2004,(2).
129. Kang JK.Park YH.Choi SW,et al.Resveratrol derivatives potently induce apoptosis in human promyelocytic leukemia cells[J].Exp Mol Med.2003,35(6):467-474.
130. Xia DY, Sanders A, Shah, M, et al.Rela-time polymerase chain reaction analysis reveals an evolution of cytokine mRNA production in allograft acceptor mice[J].Transplantation,2001, 72 (5):907-914.
131.刘吉成.低分子量姬松茸多糖抗肿瘤转移作用及其分子机制研究[D].北京中医药大学博士学位论文,2006：77-78
132.张翠梅.苦参碱诱导K562细胞γ珠蛋白基因表达和向红系分化的研究[D].广州：南方医科大学博士学位论文,2007：38.
133.吴峰,王清明,范国才,陈吉中,陈惠鹏,.紫杉醇诱导MCF-7乳腺癌细胞凋亡的蛋白质组研究[J].中华肿瘤杂志,2006,(6).
134.Hou Q, Cymbalyuk E, Hsu SC, et al.Apoptosis modulatory activities of transiently expressed Bcl-2:roles in cytochrome C release and Bax regulation [J].Apoptosis, 2003,8 (6):617-629.
135.[102]赵晓艳,胡玉娜,康向东,等.熊果酸诱导人胃癌BGC823细胞凋亡及其作用机制初探[J].中国癌症杂志,2010,20(2)：101-104.
136. Rawat S, Gray C, Johnson TS, et al.Apoptosis and expression of BCL-2 and BAX in cyclosporine-induced experimental renal fibrosis[J].Transplant Proc,2003,35(1):187-188.
137.朱艳琴,刘粉霞,徐玉芳,等.苦参素诱导人胃癌MGC-803细胞凋亡的体内外实验研究[J].中国药学杂志,2011,46(1)：28-30.
138.于观贞,王杰军,陈颖,倪灿荣,朱明华,.转移相关基因nm23和P53及S100A4在晚期胃癌中的表达及与侵袭转移的相关性研究[J].中华胃肠外科杂志,2006,(2).
139.陈晓峰,丁嘉安,王海峰,何国钧,周清华,张尚福.肺癌术后转移及预后与转移抑制基因nm23和nm23-H_1的关系[J].中华实验外科杂志,2002,(1).
140.易基群,曾波航,杨晓明,方嫩.nm23-H-1和nm23-H-2在人乳腺癌中的表达及其临床意义[J].中国癌症杂志,2001,(1).
141.杨进益,章咏裳,李韶,周荣祥,周四维,侯成玉,.膀胱移行细胞癌nm23-H1和nm23-H2基因表达的检测及临床意义[J].中华实验外科杂志,1998,(3).
142.聂强,朱文,刘伦旭,付军科,李定彪,李印,陈军,刘红雨,周清华,.nm23-H1基因转染对人高转移大细胞肺癌细胞株生物学行为的影响及作用机理[J].中国肺癌杂志,2008,(3).
143.亚威,徐广‘涛,吕仕才,潘晓燕,nm23、BRCA-1和ki-67在乳腺癌中的表达及临床意义[J].实用肿瘤杂志,2011,(1).
144.周士珍,吴强,吴正升,凌晓光,杨枫.乳腺癌中环氧化酶-2的表达及其与VEGF、MVD、 MMP-9、TIMP-1的关系[J].临床与实验病理学杂志,2005,(4).
145.王祥军,吴新勇,何长青,蔡安庆,.CD147和MMP-9在乳腺癌中的表达及其与微血.管生成的相关性研究[J].现代肿瘤医学,2010,(7).
146.梁运霞,陈茂怀,黄博,吴贤英,.细胞外基质金属蛋白酶诱导因子及金属蛋白酶-9在乳腺癌中的表达及其意义[J].癌变.畸变.突变,2007,(4).
147.王岩,刘晓霞,侯正文,柳春晖,马秀萍,陈丽萍,贾支红,方虹.基质金属蛋白酶及其抑制剂在乳腺癌转移、浸润中的作用[J].临床与实验病理学杂志,2002,(3).
148.葛凤霞,王海,冯悦年,栾风云,金岩,冯晓梅MMP-2、MMP-9和Ⅳ型胶原在乳腺癌中的表达及其意义[J].临床肿瘤学杂志,2003,(3).
149.徐峰,黄波,王劲等.红花注射液治疗冠心病心绞痛疗效观察[J].人民军医,2004,47(6)：318-319
150.齐菲菲,贺福初,姜颖,.肿瘤转移研究的现状与趋势[J].生物化学与生物物理进展,2009,(10).
151.温玉明,潘剑,华成舸,陈绍维,王吕美VEGF-C在舌鳞癌中的表达及其意义[J].中国口腔颌面外科杂志,2003,(1).
152.汤钊猷.复发与转移——原发性肝癌研究的一个重点[J].中华肝胆外科杂志,1999,(1).
153.朱延波,王瑞年.肿瘤浸润、转移与细胞外基质关系[J].上海第二医科大学学报,1992,(2).
154.唐旭东,周克元,侯敢,等.白藜芦醇诱导鼻咽癌细胞CNE-2Z凋亡的线粒体机制[J].中国药理学与毒理学杂志,2004,18(3)：171-177.
155.朱峰.基质金属蛋白酶及其组织抑制物与肿瘤侵袭转移[J].国外医学.临床生物化学与 检验学分册,2001,(5).
156.左衍海,施鑫,.恶性肿瘤转移机制研究新进展[J].医学研究生学报,2008,(3).
157.李娜,高俊岩,刘敏,.细胞凋亡和肿瘤的关系研究进展[J].当代医学,2009,(16).